Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many NHS trusts are providing Tofersen through the Early Access to Medicines Scheme.

The Early Access to Medicines Scheme (EAMS) is a programme led by the Medicines and Healthcare products Regulatory Agency (MHRA) which aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeutics.

Tofersen is not available via EAMS. Some National Health Service hospitals may sign an agreement with the manufacturer of tofersen, Biogen, to provide pre-license access. NHS England does not have any involvement in non-EAMS early access programmes.

NHS England does not hold any data on the number of NHS trusts or patients accessing tofersen through company led early access programmes.